Immuneering (IMRX) Net Cash Flow (2020 - 2024)
Historic Net Cash Flow for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$9.1 million.
- Immuneering's Net Cash Flow fell 493.85% to -$9.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$23.3 million, marking a year-over-year decrease of 7580.66%. This contributed to the annual value of -$23.3 million for FY2024, which is 7580.66% down from last year.
- Latest data reveals that Immuneering reported Net Cash Flow of -$9.1 million as of Q4 2024, which was down 493.85% from -$14.5 million recorded in Q3 2024.
- Immuneering's Net Cash Flow's 5-year high stood at $56.7 million during Q3 2021, with a 5-year trough of -$36.0 million in Q3 2023.
- Moreover, its 5-year median value for Net Cash Flow was -$5.0 million (2021), whereas its average is $71503.9.
- In the last 5 years, Immuneering's Net Cash Flow soared by 172338.02% in 2021 and then crashed by 21231.24% in 2023.
- Quarter analysis of 5 years shows Immuneering's Net Cash Flow stood at $31.5 million in 2020, then tumbled by 201.74% to -$32.0 million in 2021, then skyrocketed by 88.2% to -$3.8 million in 2022, then plummeted by 128.37% to -$8.6 million in 2023, then dropped by 4.94% to -$9.1 million in 2024.
- Its last three reported values are -$9.1 million in Q4 2024, -$14.5 million for Q3 2024, and -$6.6 million during Q2 2024.